Simpson v. Ethicon, Inc.

CourtDistrict Court, N.D. Ohio
DecidedSeptember 21, 2020
Docket5:20-cv-01237
StatusUnknown

This text of Simpson v. Ethicon, Inc. (Simpson v. Ethicon, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Simpson v. Ethicon, Inc., (N.D. Ohio 2020).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

NEBRA SIMPSON, ) CASE NO. 5:20-cv-1237 ) ) JUDGE SARA LIOI PLAINTIFF, ) ) vs. ) MEMORANDUM OPINION ) AND ORDER JOHNSON & JOHNSON, et. al., ) ) ) DEFENDANTS.

Nebra Simpson began this action by filing a Short Form Complaint against Ethicon, Inc. and Johnson & Johnson1 as part of multidistrict litigation (MDL 2327) assigned to the United States District Court for the Southern District of West Virginia. On June 5, 2020, the case was transferred to this Court for final resolution. (Doc. No. 31 Transfer Order [“Transfer Order”] at 1327.)2 Now before the Court is the motion filed by defendants Ethicon LLC and Johnson & Johnson (collectively “Ethicon” or “defendants”) to exclude the expert testimony of Dr. John P. Brennan (“Dr. Brennan”). (Doc. Nos. 26 & 27 [“Mot.”].) Plaintiff Nebra Simpson (“Simpson” or “plaintiff”) filed a brief in opposition, (Doc. Nos. 28 & 29 [“Opp’n]), and defendants replied (Doc. No. 30 [“Reply”]). For the reasons set forth herein, the motion is granted in part and denied in part.

1 Ethicon LLC was also named as a defendant in the Long Form Amended Complaint but was dismissed from the case on June 19, 2020. (Doc. No. 56 Joint Stipulation of Dismissal.) 2 All page number references are to the page identification number generated by the Court’s electronic docketing system. I. Portions of Dr. Brennan’s testimony are inadmissible because they are not relevant. Fed. R. Evid. 702, addressing the testimony of expert witnesses, “requires that the evidence or testimony assist the trier of fact to understand the evidence or to determine a fact in issue. This condition goes primarily to relevance. Expert testimony which does not relate to any issue in the case is not relevant and, ergo, non-helpful.” Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579,

591, 113 S. Ct. 2786, 125 L. Ed. 2d 469 (1993) (internal citations omitted). “[A] party proffering expert testimony must show by a ‘preponderance of proof’ that the expert … will testify to scientific knowledge that will assist the trier of fact in understanding and disposing of issues relevant to the case.” Pride v. BIC Corp., 218 F.3d 566, 578 (6th Cir. 2000) (citation omitted). To be relevant, evidence must have a “tendency to make a fact more or less probable than it would be without the evidence” and must be “of consequence in determining the action.” Fed. R. Evid. 401. Evidence that is not relevant is not admissible. Fed. R. Evid. 402. A. Dr. Brennan’s testimony, to the extent it concerns general causation, is not relevant because he has been designated as a specific-causation expert. “In toxic tort cases, the causation inquiry is two-pronged. First, a plaintiff must show that the substance to which she was exposed can cause the type of injury alleged [general causation]. Next, a plaintiff must show that in her case, exposure to the substance actually caused the alleged injury [specific causation].” In re Meridia Prod. Liab. Litig., 328 F. Supp. 2d 791, 798 (N.D. Ohio 2004), aff’d sub nom. Meridia Prod. Liab. Litig. v. Abbott Labs., 447 F.3d 861 (6th Cir. 2006) (citing Sterling v. Velsicol Chem. Corp., 855 F.2d 1188 (6th Cir. 1988); Bonner v. ISP Techs. Inc., 259 F.3d 924, 928 (8th Cir. 2001)); see also In re Hanford Nuclear Rsrv. Litig., 292 F.3d

1124, 1129 (9th Cir. 2002); Goebel v. Denver & Rio Grande W. Ry. Co., 346 F.3d 987, 990 (10th Cir. 2003); Guinn v. AstraZeneca Pharm. LP, 602 F.3d 1245, 1249 n.1 (11th Cir. 2010). 2 “Where an expert is designated as a case-specific causation expert, his or her expert testimony concerning causation must be tailored to only the specific causation opinions concerning the case at hand. That said, such testimony ‘may necessarily include elements of general causation related to [the] specific causation opinions.’” Owens v. Ethicon, Inc., No. 3:19-cv-80, 2020 WL

1976642 at *4 (E.D. Ky. Apr. 24, 2020) (citing In re: Ethicon, Inc. Pelvic Repair Sys. Prod. Liab. Litig., No. 2327, 2016 WL 4958297, at *1 (S.D. W.Va. Aug. 25, 2016) (admitting a case-specific causation expert’s general causation opinions because they were “offered only to link the typical mesh defect characteristics with the alleged injuries to [the plaintiff]”). See In re Ethicon, Inc. Pelvic Repair Sys. Prod. Liab. Litig., No. 2:12-cv-737, 2016 WL 7242550 at *2 (S.D. W.Va. Dec. 14, 2016) (excluding general causation testimony given by a case-specific causation expert); see also Thomas v. Novartis Pharm. Corp., 443 F. App’x 58, 64 (6th Cir. 2011) (excluding specific- causation testimony given by general-causation expert witnesses); Z.H. v. Abbott Labs., Inc., No. 1:14-cv-176, 2017 WL 57217, at *3 (N.D. Ohio Jan. 5, 2017) (excluding general-causation and specific-causation testimony given by a non-causation expert witness); Ashburn v. Gen. Nutrition

Centers, Inc., No. 3:06-cv-2367, 2007 WL 4225493, at *5 (N.D. Ohio Nov. 27, 2007) (excluding specific-causation testimony given by general-causation expert witnesses). Defendants argue that Dr. Brennan’s case-specific testimony includes general causation opinions that (1) TVT is a “defective mesh”; (2) risks and complications outweigh the benefits of the use of TVT; and (3) “feasible, safer alternatives to this device have existed for patients[.]” (Mot. at 1278.) Because Dr. Brennan was not identified as a general causation expert, defendants contend that those opinions are not admissible. (Id. at 1277–79.) Plaintiff responds that Dr. Brennan’s testimony is admissible because he only opines about general causation in order to “lay[] the foundation for his case-specific opinion.” (Opp’n at 1314.) 3 The Court analyzes the first and second statements here and the third statement in Section B. 1. “[T]he defective mesh implanted in [plaintiff] in July, 2009 was the cause of her multiple symptoms and complications.” This is a causation-specific opinion as it concerns what caused plaintiff’s injuries. That Dr. Brennan describes the mesh as “defective” does not transform it into a general-causation statement. The statement is admissible. To that extent, defendants’ motion is denied. 2. “[T]he benefits of the mesh are outweighed by the severe, debilitating and life changing complications associated with the device.”

This is a general causation statement about defendants’ device. It does not “lay[] the foundation” for a case-specific opinion about plaintiff’s condition because it does not concern plaintiff’s alleged complications and injuries. The statement is inadmissible. To that extent, defendants’ motion is granted. B. Brennan’s opinion that “feasible, safer alternatives to this device have existed for patients” is not relevant. Defendants argue that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Guinn v. ASTRAZENECA PHARMACEUTICALS LP
602 F.3d 1245 (Eleventh Circuit, 2010)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Goebel v. Denver & Rio Grande Western Railroad
346 F.3d 987 (Tenth Circuit, 2003)
Woodrow Sterling v. Velsicol Chemical Corporation
855 F.2d 1188 (Sixth Circuit, 1988)
Heflin v. Stewart County, Tennessee
958 F.2d 709 (Sixth Circuit, 1992)
Bethie Pride v. Bic Corporation Societe Bic, S.A.
218 F.3d 566 (Sixth Circuit, 2000)
In Re Meridia Products Liability Litigation
328 F. Supp. 2d 791 (N.D. Ohio, 2004)
In Re Commercial Money Center, Inc.
737 F. Supp. 2d 815 (N.D. Ohio, 2010)
Terry Anderson v. Novartis Pharmaceuticals Corp
443 F. App'x 58 (Sixth Circuit, 2011)
Yonts v. Easton Technical Products, Inc.
676 F. App'x 413 (Sixth Circuit, 2017)
Paula Babb v. Maryville Anesthesiologists, P.C.
942 F.3d 308 (Sixth Circuit, 2019)
Medlin v. Clyde Sparks Wrecker Service, Inc.
59 F. App'x 770 (Sixth Circuit, 2003)
Huskey v. Ethicon, Inc.
29 F. Supp. 3d 691 (S.D. West Virginia, 2014)
Tyree v. Boston Scientific Corp.
54 F. Supp. 3d 501 (S.D. West Virginia, 2014)
In re C.R. Bard, Inc.
948 F. Supp. 2d 589 (S.D. West Virginia, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Simpson v. Ethicon, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/simpson-v-ethicon-inc-ohnd-2020.